Subconjunctival Injection of Low Doses of Mitomycin C: Effects on Fibroblast Proliferation

1998 ◽  
Vol 212 (5) ◽  
pp. 306-309 ◽  
Author(s):  
I. Pinilla ◽  
J.M. Larrosa ◽  
V. Polo ◽  
F.M. Honrubia
Keyword(s):  
Mitomycin C ◽  
Subconjunctival Injection ◽  
Low Doses ◽  
Fibroblast Proliferation

scholarly journals The effect of platelet-rich fibrin on normal dermal fibroblast proliferation after mitomycin-c treatment: An in vitro study

2021 ◽  
Vol 62 ◽  
pp. 473-476
Author(s):  
Ishandono Dachlan ◽  
Hendy Satrya Kurniawan ◽  
Aditya Wicaksana ◽  
Aditya Rifqi Fauzi ◽  
Firdian Makrufardi ◽  
...  
Keyword(s):  
Mitomycin C ◽  
Dermal Fibroblast ◽  
In Vitro Study ◽  
Vitro Study ◽  
Fibroblast Proliferation ◽  
Platelet Rich Fibrin

scholarly journals Adjunctive Antifibrotic Therapy with Mitomycin C and 5-Fluorouracil: A Review of their use in Glaucoma Surgery and Considerations around Ophthalmic Compounding

2019 ◽  
pp. 154-169
Author(s):  
Fiscella R ◽  
Leiter CW ◽  
Massoomi F ◽  
Noecker R ◽  
Sheybani A
Keyword(s):  
Minimally Invasive ◽  
Mitomycin C ◽  
Drug Safety ◽  
Glaucoma Surgery ◽  
Subconjunctival Injection ◽  
Drug Products ◽  
Antifibrotic Therapy ◽  
Effective Use ◽  
Different Doses ◽  
The U.S

Background: Antifibrotics and antimetabolites, including 5-fluorouracil (5-FU) and mitomycin C (MMC), have been used for decades to improve ophthalmic surgical outcomes, most notably with glaucoma filtering procedures. Adjuvant MMC and 5-FU also enhance the efficacy of minimally invasive subconjunctival drainage implants now being used. The authors feel that a review of the usage and safety of these agents is merited, especially in light of updated and new USP guidelines for compounded and hazardous drugs.Main Body: The mode of perioperative administration of MMC during glaucoma surgery is evolving with a shift from the traditional sponge application to subconjunctival injection, allowing for a more precise dosing and controlled administration of this medication. Several studies demonstrate effective use of MMC and 5-FU, at a variety of different doses. Most of these studies use compounded MMC and 5-FU. Glaucoma surgeons must be careful in how they source MMC, however, as the U.S. Food & Drug Administration (FDA) expects physicians to use FDA-approved drug products when clinically appropriate. When a physician determines a compounded version of MMC is clinically necessary for an individual patient, the FDA closely regulates how and when drug products can be compounded and by what type of facilities. There will also be additional increased scrutiny on storage and disposal of MMC and 5-FU as new regulations are introduced.Conclusion: This review of MMC and 5-FU and their role in glaucoma surgery will address questions regarding drug safety, procurement, use, and disposal.

Long-Term Effects of Postoperative Subconjunctival Injections of Mitomycin-C in the Rabbit Eye

1997 ◽  
Vol 7 (4) ◽  
pp. 340-344 ◽  
Author(s):  
L.E. Pablo ◽  
T. Ramirez ◽  
M. Pueyo ◽  
J.M. Larrosa ◽  
V. Polo ◽  
...  
Keyword(s):  
Mitomycin C ◽  
Subconjunctival Injection ◽  
Long Term Effects ◽  
Rank Tests ◽  
Surgical Sponge ◽  
Operative Evaluation ◽  
Bleb Failure ◽  
Pigmented Rabbits ◽  
Survival Differences

Aim Single or multiple subconjunctival injections of mitomycin-C (MMC) may offer one way of establishing the total dosage of MMC more accurately. The method also allows re-applications later postoperatively. In this experimental, randomized prospective study we compared the effects of a single intraoperative application of MMC at the filtering site and a single postoperative subconjunctival injection of the drug. Methods The left eyes of 32 pigmented rabbits were divided into two groups. In the first group we applied MMC intraoperatively (10) with a 4×1 mm surgical sponge soaked in a MMC solution (0.5 mg/ml). In the second group we injected 0.4 ml of the same solution subconjunctivally (SC) immediately after (conjunctival) suture. Post-operative evaluation was carried out every day during the first week, then every three days until day 58. Survival analyses were done for intraocular pressure (IOP) and bleb failure. Log-rank tests were used to compare survival differences between the groups. Results The IO group showed longer survival parameters than the SC group (p<0.05), both in the control of IOP and as regards blebs. The histological persistence of fistulas was similar. The IO group, however, had a higher incidence of undesirable side effects. Conclusions Our findings suggest IO application of MMC is more effective in reducing fibroblast ingrowth. However, subconjunctival application offers certain advantages such as the possibility of repeating the treatment postoperatively and, therefore, using a smaller initial dose.

Sign in / Sign up

Export Citation Format

Share Document